Result:Poor· Market: Flat#Margin squeeze
| Metric | Value (₹ Cr) | Q4 FY26 | Q1 FY26 |
|---|---|---|---|
| Revenue | 1.43 | 32.6% | 3.4% |
| Total Income | 1.75 | 27.0% | 2.7% |
| Expenditure | 2.32 | 8.8% | 57.8% |
| PBT | -0.57 | 284.3% | 275.3% |
| Net Profit | -0.57 | 284.3% | 275.3% |
| OPM | -62.48% | 42.46pp | 56.10pp |
| NPM | -32.76% | 26.54pp | 50.94pp |
| EPS | 0.01 | 0.0% |
Pharma/biotech core profitability collapsed—revenue barely grew (3.3% YoY) while the company swung from a ₹0.33cr profit to a ₹0.57cr loss as OPM crashed from -6.4% to -62.5%, a clear deterioration rather than a turnaround.
Informational and educational content only. Not investment advice.